scispace - formally typeset
D

David E. Newby

Researcher at University of Edinburgh

Publications -  902
Citations -  45577

David E. Newby is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Myocardial infarction & Coronary artery disease. The author has an hindex of 98, co-authored 805 publications receiving 35865 citations. Previous affiliations of David E. Newby include NHS Lothian & Queen's University.

Papers
More filters
Journal ArticleDOI

Identification of early vascular calcification with (18)F-sodium fluoride: potential clinical application.

TL;DR: Investigating the early and dynamic stages of vascular calcification through the use of the positron-emitting radiotracer, 18F-sodium fluoride has raised promise that exploring this process may allow improved risk prediction, better application of current therapies and ultimately the development of novel treatments to target this widespread pathology.
Journal ArticleDOI

Automated nonlinear registration of coronary PET to CT angiography using pseudo-CT generated from PET with generative adversarial networks

TL;DR: In this article , a novel fully automated method to register coronary 18F-NaF positron emission tomography (PET) to CT angiography using pseudo-CT generated by generative adversarial networks (GAN) was developed.
Journal Article

Comparison of forearm vasodilatation to substance P and acetylcholine

TL;DR: In healthy men, a greater proportion of the forearm vasodilatation to substance P than to acetylcholine appears to be nitric oxide-mediated, and substance P may be more suitable as a pharmacological tool in the investigation of stimulatedNitric oxide production and endothelial cell function.
Journal ArticleDOI

Endovascular repair for abdominal aortic aneurysms

TL;DR: In this article, the authors present a review of current EVAR practice, recent updates in clinical practice guidelines and the potential future developments to facilitate the selection of mode of aneurysm repair.
Journal ArticleDOI

Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men

TL;DR: The absence of a rise in plasma endothelin levels suggests BMS-193884 is selective for the ET(A) receptor, and this form of pharmacodynamic modelling may be useful in the development of ERAs in cardiovascular disease.